94% of Healthcare Execs Say AI, Blockchain Have Advanced Innovation

Healthitanalytics | June 06, 2019

Ninety four percent of healthcare executives report that artificial intelligence, blockchain, and other emerging technologies have accelerated the pace of innovation over the past three years, according to an Accenture report.However, the report also found that while technology investments have progressed, healthcare organizations still need to do more to meet rising consumer and employee expectations. The healthcare industry has largely come to recognize that digital technologies must be a core part of everyday processes, with organizations increasingly investing in social, mobile, analytics, and cloud technologies. Eighty percent of healthcare executives agreed that these tools have moved beyond adoption silos to become an integral part of the technology foundation of their organizations.

Spotlight

Hospitalized patients who experience sudden unanticipated serious deterioration and subsequent cardiorespiratory arrests have very poor outcomes. In addition, the institutional and patient costs of such events are quite high. A significant number of avoidable adverse and sentinel events occur on the medical-surgical floor, where nurse to-patient ratios often prevent continuous direct patient observation. Many of the patients that suffer either serious deterioration or sudden death have preceding predictive events. Continuous monitoring of vital signs can provide early detection of deterioration and may improve patient outcomes. A report by the Institute for Health Care Improvement (IHI) suggests that in many instances, subjective complaints and changes in vital signs could be noticed hours or even days in advance of cardiac or respiratory arrests, and majority of the events were observed to be preventable.


Other News
DIGITAL HEALTHCARE

Hekka Labs Introduces the First Decentralized Chronic Disease Data Management Ecosystem in South Asia

Hekka Labs | January 15, 2022

Hekka Labs launches a game changing decentralized healthcare ecosystem for a far more efficient health record management. The firm will concentrate on the Southeast Asia market, starting with India, where it will establish the largest chronic disease data management network. Hekka then intends to connect to the rest of the world's healthcare market through the design and implementation of proprietary Distributed Ledger Technology (DLT). Hekka has cemented initial partnerships with 3 Indian healthcare solution providers, Curisin, a healthcare company with a wide network of 30 million patients and 40,000 partnered doctors which as recently agreed to provide a minimum of 1.5 million medical records in 2022. A further agreement to provide up to 20 separate blood biomarkers together with Covid 19 data on 100,000 patients, will form the basis of an initial trial for its blockchain audit trail platform. IMMUNIDEX, a healthcare solution provider offering tests and applications that are driven by proprietary AI that can identify early immune-related risks and is well placed to capture highly valuable data for the Hekka network. TELEMEDICINE INDIAN CO, a start-up offering multi telemedicine services, multiple blood tests, and health screening including COVID-19 testing will form another integral part of data generation for the Hekka ecosystem. Hekka Labs with the integration of Distributed Ledger Technology (DLT) offers a plug and go solution that allows users to interact with the HEKKA ecosystem without major disruption. This set up can solve the inherent problems that occur on a regular basis in the healthcare industry such as inefficient biomarker management, document hogging and unstructured data management. Hekka Labs has set out to become the leading chronic illness and immunology platform in India. Hekka's private and public blockchain network solution will generate a new trust in Indian healthcare data management and can open up significant opportunity for both the domestic and global collaboration. This will lead to new levels of ethical standards and excellence for the Indian healthcare market. In the long run, Hekka plans to evolve as a significant decentralized healthcare ecosystem by connecting the network of medical and associated healthcare providers culminating in a targeted community of over 500 million patients. As a result, tens of billions of chronic disease digital biomarkers can be made available for Deep Learning, potentially speeding up new healthcare discoveries. HEK is the native token of the Hekka ecosystem, which is launched in the Ethereum network's ERC-20 standards for its intensive security and global reputation, ensuring the confidence of delivering the most sophisticated healthcare data management service. The HEK token is a token complimented by an ATOM token (Points) system which is the primary source of HEKKA 's data transfers. This ensures the value of the token. The HEK token will be a key component in serving all prospective users' interactions with the platform's different levels of service.

Read More

MEDICAL DEVICES

GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

GeneQuantum Healthcare | May 16, 2022

GeneQuantum Healthcare Co., Ltd. a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugateboth with global intellectual property rights. "The core technologies that we have focused on since the founding of GeneQuantum, bring the company into the harvest period for exciting next generation bioconjugate drugs. The EC approval of GQ1005 and GQ1007 in Australia is an important milestone for the company. More than once, GeneQuantum's enzymatic site-specific conjugation platform and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates. GeneQuantum conjugation technologies are widely compatible to different molecular modalities with various Mechanism of Action. Committed to the core value of "breakthrough for humanity", GeneQuantum is dedicated to developing safe, effective, and affordable novel therapeutics for patients with cancer around the world." Dr. Gang Qin, founder, Chairman and Chief Executive Officer About GeneQuantum Healthcare Co., Ltd. GeneQuantum Healthcare Co., Ltd. is a global biotechnology company dedicated to the development of innovative biotherapeutics. The company is focused on the development of next generation bioconjugate therapeutics to address the unmet medical needs of patients globally. This press release contains statements relating to GeneQuantum's future business, future events or developments, and related statements may constitute forward-looking statements. Statements are based on current expectations and assumptions that are subject to risks and uncertainties, which may cause actual results to differ materially. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, follow-up clinical data and analysis; factors that may cause any delay, transfer or change; regulatory authority decision whether and when to approve drug applications; factors that may lead actual results to seriously deviate from current expectations, etc. No forward-looking statement can be guaranteed. Except as required by applicable laws, GeneQuantum assumes no obligation to update or revise any forward-looking information or statements.

Read More

INSURANCE

As One Insurance Group Launches Population Health Strategy That is Revolutionizing Healthcare

As One Insurance Group | February 25, 2022

Privately-held insurance brokerage firm As One Insurance Group ("As One") has announced the launch of its population health strategy that is already revolutionizing the healthcare industry based in Phoenix, As One has quickly achieved benchmark status in the population health world. Brandon Bullock, Chief Strategy Officer of As One, says, "Over the years we have seen the number of those without access to healthcare shrink, the numbers are a positive sign, 10 percent of Americans still have no access to care. We're looking to close that gap. As One is offering Health Navigator alongside its proprietary sales platform which leverages electronic processing to speed up the sales cycle." The cutting-edge firm specializes in life, health, and ancillary insurance benefits and is making insurance simple for carriers, agents, and clients through distinct offerings including: An innovative population health strategy A proprietary sales platform and CRM for straight-through electronic processing An impressive nationwide distribution channel Advanced agent training and sales tools "With the right tools at their fingertips, our team and agents show tremendous courage every day fighting to fix health insurance, a strong team that works as one." J.R. Jordan, Chief Executive Officer of As One Cost of Healthcare in America The cost of Healthcare in the United States is a significant factor that prevents people from obtaining the necessary care or filling prescriptions. Half of U.S. adults have stated that they postponed or completely mitigated some sort of dental or health care in the past year due to the high cost. Three in 10 people have also reported not taking their necessary medicines as prescribed at some point due to the very same reason. High healthcare costs excessively affect uninsured adults and those with lower household incomes. Larger shares of U.S. adults have also reported difficulty affording different types of care, which further delays and attributes to them forgoing medical care due to the cost. However, individuals that are covered by health insurance are not immune to the weight of healthcare costs. Almost half (46%) of those insured reported difficulty affording out-of-pocket expenses, and 27% had reported difficulty in being able to afford their deductible. Difficulty paying medical bills has resulted in significant consequences for U.S. families. Medical bill problems are also disproportionately affecting those adults in households where they or a member of their household has a severe health condition. About As One Insurance Group As One Insurance Group ("As One") is a privately held insurance brokerage based in Phoenix, Arizona, specializing in life, health, and ancillary insurance benefits. As One aims to simplify insurance by making the process straightforward and honest. With transparent product information and open communications being the norm, the company provides a range of life and health insurance products that are coupled with the tools agents and clients need to manage their needs. That includes advanced education and training, innovative technology solutions, and best-in-class service. In short, they work with and for agents, clients, and carriers together as one.

Read More

FUTURE OF HEALTHCARE

Omega Healthcare completes acquisition of ApexonHealth and Vasta Global

Omega Healthcare | April 18, 2022

Omega Healthcare, a leading technology-enabled healthcare management solutions provider,announced its acquisition of ApexonHealth, an AI and automation-based revenue cycle management and payor solutions provider, and Vasta Global, a provider of real-world data abstraction and analytics for the oncology market. ApexonHealth leverages its digital solutions to deliver comprehensive technology-enabled services for both providers and payors from revenue cycle management and coding to claims management and advanced analytics. ApexonHealth's cognitive and automation capabilities have significantly reduced manual effort and increased accuracy in claims adjudication strengthening its payor services. ApexonHealth's expertise in the healthcare payor sector will augment Omega's existing payor-focused offerings. Vasta Global provides clinical data management with a focus on the oncology market and provides real-world evidence data curation and analytics, clinical trial support, and cancer registry services for cancer centers. Vasta Global's customers span the entire healthcare ecosystem including providers, pharmaceutical and biotechnology companies, and contract research organizations that provide clinical trial management services. The two acquisitions will complement Omega Healthcare's existing strengths in revenue cycle management and clinical data management for various medical registries including cancer, stroke, and trauma. These acquisitions are part of the strategy to accelerate Omega's journey in scaling its portfolio of AI- and data-analytics- based solutions to help healthcare clients optimize revenue while reducing cost through leveraging of big data and automation technology. With the recently completed acquisition of Reventics, Omega Healthcare will deliver an end-to-end revenue cycle management suite of solutions to healthcare providers, from analytics-driven clinical documentation improvement to platforms for payment data management. The Company will also expand its oncology-focused offering to now include big data capture and reporting to help healthcare providers and pharmaceutical companies leverage complex, longitudinal data to improve cancer treatment. "We are pleased to welcome ApexonHealth and Vasta Global to the Omega family. We've been very impressed by the vision and execution by the two management teams. Bringing together the Omega, ApexonHealth, and Vasta offerings together will unlock significant value to our clients." Anurag Mehta, CEO of Omega Healthcare "I am thrilled about this opportunity to join the Omega platform. Our mission to provide sustainable and scalable solutions to our clients is one that is shared by the Omega Healthcare team. With their broad capabilities, we are excited to offer our clients access to data curation, registry management, and machine learning solutions. Through this alliance, we reinforce our commitment to scientific discovery for patients through accelerated clinical research and real-world data," said Kinjal Vora, CEO of Vasta Global. "We are pleased to welcome ApexonHealth and Vasta Global to the Omega family," commented Harsh Nanda, Managing Director and Head of Technology Private Equity within Goldman Sachs Asset Management. "With the acquisitions of Reventics, ApexonHealth, and Vasta Global, Omega now services more than 350 customers spanning the entire healthcare continuum with the support of robust technology-led solutions and insights. Together, we can help our clients enhance the patient experience while improving operational efficiency and strengthen our position as the partner of choice for the healthcare ecosystem." About Omega Healthcare Founded in 2003, Omega Healthcare helps payors, providers, and pharmaceutical companies eliminate administrative burdens, accelerate cash flow, and reduce health management costs while enhancing patient care. The company streamlines medical billing, coding, and collections processes and provides virtual nursing services, including triage, care continuation, clinical documentation improvement, and re-admittance avoidance. Combining the largest medical coding staff in the world with proprietary technology, analytics, and automation capabilities, Omega Healthcare provides the most comprehensive outsourced solutions in the industry and is ranked among the top revenue cycle management business process services by industry analysts. About ApexonHealth Founded in 1996, ApexonHealth provides healthcare-focused digital solutions that combine the best of cutting-edge technology around machine learning, workflow automation, and business process automation to deliver comprehensive services for both providers and payors from revenue cycle management and coding to claims management and advanced analytics. Having helped 80+ healthcare organizations in 14+ years transform their RCM systems, ApexonHealth is actively involved and supports various healthcare bodies like the American Health Information Management Association (AHIMA), American Academy of Professional Coders (AAPC), and more. About Vasta Global Vasta Global offers solutions for data management, clinical research, bioinformatics consulting, and business process outsourcing. With over a decade of experience in cancer research and medical information management, Vasta Global is committed to providing sustainable and scalable solutions for clinical research and bioinformatics needs. The company's information technology and data management solutions streamline and integrate research and patient care workflows while collecting quality data, achieving research goals, and shaping the clinical practice guidelines of tomorrow. About Goldman Sachs Asset Management Bringing together traditional and alternative investments, Goldman Sachs Asset Management provides clients around the world with a dedicated partnership and focus on long-term performance. As the primary investing area within Goldman Sachs, we deliver investment and advisory services for the world's leading institutions, financial advisors and individuals, drawing from our deeply connected global network and tailored expert insights, across every region and market—overseeing more than $2 trillion in assets under supervision worldwide as of December 31, 2021. Driven by a passion for our clients' performance, we seek to build long-term relationships based on conviction, sustainable outcomes, and shared success over time. About Everstone Capital Partners Everstone is a premier investment group focused on cross-border North America – Asia investments and domestic investments in India and Southeast Asia, with assets of ~US$7 billion across private equity, real estate, credit, climate change and green infrastructure, and venture capital. Everstone has a significant resource base across its seven offices in Singapore, India, New York, Mauritius and UAE, comprising best-of-breed investing, operations and strategic resources with extensive skills and experience.

Read More

Spotlight

Hospitalized patients who experience sudden unanticipated serious deterioration and subsequent cardiorespiratory arrests have very poor outcomes. In addition, the institutional and patient costs of such events are quite high. A significant number of avoidable adverse and sentinel events occur on the medical-surgical floor, where nurse to-patient ratios often prevent continuous direct patient observation. Many of the patients that suffer either serious deterioration or sudden death have preceding predictive events. Continuous monitoring of vital signs can provide early detection of deterioration and may improve patient outcomes. A report by the Institute for Health Care Improvement (IHI) suggests that in many instances, subjective complaints and changes in vital signs could be noticed hours or even days in advance of cardiac or respiratory arrests, and majority of the events were observed to be preventable.

Resources